CYMODIQ Trademark

Trademark Overview

On Friday, October 11, 2019, a trademark application was filed for CYMODIQ with the United States Patent and Trademark Office. The USPTO has given the CYMODIQ trademark a serial number of 88651053. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 8, 2023. This trademark is owned by Pfizer Inc.. The CYMODIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
cymodiq

General Information

Serial Number88651053
Word MarkCYMODIQ
Filing DateFriday, October 11, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 8, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 11, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 17, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, May 8, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 8, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, April 6, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, April 6, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 6, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 6, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 6, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, September 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 19, 2022SOU EXTENSION 5 GRANTED
Wednesday, September 14, 2022SOU EXTENSION 5 FILED
Wednesday, September 14, 2022TEAS EXTENSION RECEIVED
Friday, March 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 2, 2022SOU EXTENSION 4 GRANTED
Wednesday, March 2, 2022SOU EXTENSION 4 FILED
Wednesday, March 2, 2022TEAS EXTENSION RECEIVED
Saturday, August 28, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 26, 2021SOU EXTENSION 3 GRANTED
Thursday, August 26, 2021SOU EXTENSION 3 FILED
Thursday, August 26, 2021TEAS EXTENSION RECEIVED
Tuesday, March 2, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 26, 2021SOU EXTENSION 2 GRANTED
Friday, February 26, 2021SOU EXTENSION 2 FILED
Friday, February 26, 2021TEAS EXTENSION RECEIVED
Wednesday, July 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 20, 2020SOU EXTENSION 1 GRANTED
Monday, July 20, 2020SOU EXTENSION 1 FILED
Monday, July 20, 2020TEAS EXTENSION RECEIVED
Wednesday, June 17, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, June 17, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, May 4, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, May 4, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, May 4, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, May 4, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 4, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, May 4, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, April 7, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 11, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 11, 2020PUBLISHED FOR OPPOSITION
Wednesday, January 22, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 8, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 8, 2020ASSIGNED TO EXAMINER
Thursday, October 17, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 15, 2019NEW APPLICATION ENTERED

Related Keywords

cymodiq preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological